Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.86B 3.38B 3.12B 2.92B 5.47B 364B 5.58B 37.45B 14.49B 180B 14.48B 14.16B 623B P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 3.86B 3.38B 3.12B 2.92B 5.47B 364B 5.58B 37.45B 14.49B 180B 14.48B 14.16B 623B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.37x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week+0.22%
Current month+0.70%
1 month+0.70%
3 months+32.25%
6 months+30.71%
Current year+34.75%
1 week 31.37
Extreme 31.37
31.5
1 month 31.25
Extreme 31.25
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Chairman 78 01/01/2002
Director/Board Member 80 19/02/2015
Director/Board Member 62 01/10/2002
Date Insider Type Main position Quantity % Market Cap.
03/06Fiscal year

Chief Technology Officer

3,795 0.0031%
17/02Fiscal year

Head of Human Resources

1,585 0.0013%
05/01Fiscal year

Chief Financial Officer

16,358 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+0.22%+44.93%+132.45% 3.86B
+0.12%+3.58%+20.85%-10.44% 64.39B
+2.13%+6.62%+58.13%+230.17% 56.12B
-3.10%+34.30%+34.30%+34.30% 40.54B
+0.45%+2.22%-51.82%-58.54% 37.98B
+0.95%+8.47%+72.49%-23.22% 31.89B
+3.15%+17.41%+152.54%-42.94% 26.69B
+0.28%+10.65%+68.43%+85.45% 22.73B
+6.52%+5.12%+3.49%+174.61% 16.66B
-0.49%+4.32%+61.00%+123.72% 16.6B
Average +0.98%+4.56%+46.43%+64.56% 31.75B
Weighted average by Cap. +0.76%+4.51%+41.61%+53.36%

Financials

2026 *2027 *
Net sales 636M 558M 514M 481M 903M 60.01B 921M 6.18B 2.39B 29.66B 2.39B 2.34B 103B 718M 629M 580M 543M 1.02B 67.72B 1.04B 6.97B 2.7B 33.47B 2.7B 2.64B 116B
Net income 231M 203M 187M 175M 328M 21.8B 335M 2.25B 869M 10.78B 868M 849M 37.37B 316M 277M 256M 239M 449M 29.83B 458M 3.07B 1.19B 14.74B 1.19B 1.16B 51.12B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
30/06/26 USD 31.45 -0.17% 371,981
26/06/26 USD 31.50 +0.25% 4,067,136
25/06/26 USD 31.42 0.00% 1,170,475
24/06/26 USD 31.42 +0.06% 1,180,755
23/06/26 USD 31.40 +0.06% 948,604
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.50USD
Average target price
31.67USD
Spread / Average Target
+0.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock